Santander International Selects Temenos and Syncordis to Launch its Digital Banking Platform in the Cloud and Become “future-ready”
6.4.2021 09:30:00 EEST | Business Wire | Press release
Syncordis, the global Temenos implementation partner and product experts, and Temenos (SIX: TEMN), the banking software company, announced that Santander International, part of the Banco Santander group, has selected Temenos SaaS, implemented by Syncordis, to power-up its core banking platform transformation.
Syncordis will help Santander International, which has branches in Jersey and the Isle of Man, to transform its banking, savings and mortgage products IT infrastructure from an on-premise solution to cloud-native Temenos SaaS. This will enable Santander International to benefit from the security, resilience and elastic scalability of the Microsoft Azure cloud.
Moving to the Temenos cloud-native and API-first digital banking platform with pre-configured banking and mortgages functionality will enable the bank to build and launch products faster and deliver enhanced digital experiences with streamlined customer journeys.
Syncordis has been selected as the system integrator and implementation partner to lead the core banking implementation and modernization project with a new digital banking eco-system. Adopting an agile implementation approach to complete the project delivery in the shortest timeframe, the bank’s customers will benefit from a smooth transition to Temenos’ next generation digital banking solution.
James Pountney, Chief Executive Officer Santander International, commented:
“In challenging times such as these, it is more vital than ever to be able to adapt to changing business and customer requirements simply, safely and swiftly. By working with Temenos and Syncordis we will be able to future-proof our digital banking platform which will enable us to provide our valued customers with outstanding service and a seamless customer experience.”
Hemal Jayasinghe, Chief Business Officer / Regional Director UK & NORDICS, Syncordis, said:
“We are excited to strategically partner with Santander International to modernize their core banking operations and drive their digitization journey. Innovation and the willingness to transform are key in today’s ever-changing world. With Temenos’ powerful cloud technology and Syncordis’ extensive implementation expertise, Santander International will be enabled to power their digital banking capabilities, provide an excellent and modern experience to their customers and future-proof their business.”
David Macdonald, President - Europe, Temenos, said:
“We’re excited to be working with Santander International to help redefine their customer experience. We see a growing momentum of banks both globally and in Europe choose Temenos as the most advanced cloud technology in the market to break free from legacy systems. Temenos SaaS delivers speed and agility while providing the security and resilience that a modern digital bank needs. We’re proud to be part of this evolution.”
Notes for Editors:
About Santander International:
Santander International is the trading name of the Jersey and Isle of Man branches of Santander Financial Services plc, a wholly owned subsidiary of Santander UK Group Holdings plc which is part of the Banco Santander group.
Santander International offers banking and savings accounts to Channel Island and Isle of Man residents, UK residents, UK expatriates, foreign expatriates and international customers. Santander International also offer mortgages on Jersey and Isle of Man properties and Corporate Banking solutions for Channel Island and Isle of Man domiciled companies. www.santanderinternational.co.uk
About Syncordis:
Syncordis, a Luxembourg based LTI Company, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software such as Temenos Infinity, Temenos Transact, Temenos Fund Administration, Temenos Infinity Wealth and Temenos DataSource. Syncordis is also the only Temenos global partner that is fully dedicated to Temenos services with capabilities to support all Temenos software suites. With 12 offices across the globe, 500+ experts and complementary services like SaaS and regulated production support services, Syncordis enables its international clients to master their digital transformation. This makes Syncordis one of the one-stop service partners for Temenos clients worldwide. For more information, please visit www.syncordisconsulting.com
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005020/en/
Contact information
Media Contact for Syncordis:
Clara Bechler
Marketing & Communication
T +49 40 369 835 12
E cbechler@syncordisconsulting.com
Media Contact for Santander International:
Susan Clark
Marketing & Communications
T +44 1534 828 011
susan.clark@santanderinternational.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom